BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics of Ro 23-6240 (AM 833), a new trifluorinated quinolone. 1987

E Weidekamm, and K Stöckel, and D Dell
F. Hoffmann-La Roche & Co. Ltd., Department of Clinical Research and Pharmaceutical Research, Basel, Switzerland.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D016576 Fleroxacin A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE. AM-833,Quinodis,Ro 23-6240,AM 833,AM833,Ro 23 6240,Ro 236240

Related Publications

E Weidekamm, and K Stöckel, and D Dell
Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
September 1987, The Journal of antimicrobial chemotherapy,
E Weidekamm, and K Stöckel, and D Dell
In vitro studies of fleroxacin (Ro 23-6240), a new trifluorinated quinolone derivative.
January 1988, Chemotherapy,
E Weidekamm, and K Stöckel, and D Dell
In vitro activity of RO 23-6240 (AM-833): a new fluoroquinolone.
April 1987, Diagnostic microbiology and infectious disease,
E Weidekamm, and K Stöckel, and D Dell
RO 23-6240 (AM-833), a new fluoroquinolone: in vitro antimicrobial activity and tentative disk diffusion interpretive criteria.
May 1987, Diagnostic microbiology and infectious disease,
E Weidekamm, and K Stöckel, and D Dell
In vitro activity of the new quinolone RO 23-6240 (AM-833) and the new cephalosporins RO 15-8074 and RO 19-5247 (T-2525) against Mycobacterium fortuitum and Mycobacterium chelonae.
August 1987, European journal of clinical microbiology,
E Weidekamm, and K Stöckel, and D Dell
In vitro activities of T-3262, NY-198, fleroxacin (AM-833; RO 23-6240), and other new quinolone agents against clinically isolated Chlamydia trachomatis strains.
July 1988, Antimicrobial agents and chemotherapy,
E Weidekamm, and K Stöckel, and D Dell
In vitro evaluation of Ro 23-6240, a new fluorinated 4-quinolone.
January 1987, Chemotherapy,
E Weidekamm, and K Stöckel, and D Dell
In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone.
April 1986, Antimicrobial agents and chemotherapy,
E Weidekamm, and K Stöckel, and D Dell
Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone.
February 1987, Antimicrobial agents and chemotherapy,
E Weidekamm, and K Stöckel, and D Dell
In vitro activity of the new 4-quinolone compound Ro 23-6240.
April 1987, European journal of clinical microbiology,
Copied contents to your clipboard!